VAX-ID® for Tuberculin Skin Testing (TST)
Tuberculosis Screening
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains one of the world’s most significant infectious diseases, with approximately 10.6 million new cases reported annually.
Although TB is both preventable and generally curable, the early identification and management of latent tuberculosis infection are critical to reducing disease transmission and supporting global TB elimination efforts. Consequently, healthcare authorities worldwide recommend TB screening for individuals and populations at increased risk of infection.
The Importance of Accurate TB Testing
The Tuberculin Skin Test (TST) continues to be one of the most widely used methods for detecting latent TB infection. As a result, ensuring accurate, consistent, and efficient intradermal administration is essential for reliable test outcomes.
Challenges of Traditional TST Administration
Conventional TST administration relies on the Mantoux technique, a procedure that requires specialized training and precise needle placement to achieve accurate results. Variations in injection depth can impact test reliability, while the technique itself can be time-consuming and may cause discomfort for patients.
How VAX-ID Improves TST Delivery
VAX-ID addresses these challenges through a single-use microneedle adaptor that enables consistent intradermal delivery with a simple perpendicular injection technique. The device is designed to improve ease of use, reduce training requirements, enhance injection accuracy, and increase patient comfort.
Key Benefits of VAX-ID for TST
- Low Pain
- Easy to Use
- No Needle-Stick Risk
- Time Saving
Supporting Global TB Elimination Efforts
By making Tuberculin Skin Testing more accurate, efficient, and accessible, VAX-ID supports improved tuberculosis screening practices and contributes to global efforts to identify and manage latent TB infection.